Teachers Retirement System of The State of Kentucky lowered its stake in Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 3.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,671 shares of the health services provider’s stock after selling 300 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Amedisys were worth $1,494,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Covestor Ltd purchased a new stake in Amedisys during the 4th quarter valued at $28,000. Allworth Financial LP purchased a new stake in Amedisys during the 1st quarter valued at $38,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Amedisys during the 1st quarter valued at $46,000. Signaturefd LLC boosted its stake in Amedisys by 295.8% during the 1st quarter. Signaturefd LLC now owns 376 shares of the health services provider’s stock valued at $65,000 after purchasing an additional 281 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Amedisys during the 1st quarter valued at $68,000. Hedge funds and other institutional investors own 93.36% of the company’s stock.
Amedisys Trading Down 3.2 %
Shares of AMED stock opened at $111.00 on Thursday. Amedisys, Inc. has a 52-week low of $101.61 and a 52-week high of $188.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.92 and a current ratio of 0.92. The firm has a market capitalization of $3.60 billion, a PE ratio of 25.87, a PEG ratio of 2.90 and a beta of 0.95. The stock has a fifty day simple moving average of $121.75 and a two-hundred day simple moving average of $129.77.
Wall Street Analyst Weigh In
Several analysts have commented on AMED shares. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 target price on shares of Amedisys in a research note on Tuesday, June 28th. Cowen lowered their price target on Amedisys to $125.00 in a report on Tuesday, August 9th. Bank of America cut Amedisys from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $145.00 to $102.00 in a report on Tuesday, June 21st. Truist Financial lowered their price target on Amedisys from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Thursday, July 14th. Finally, Oppenheimer lowered their price target on Amedisys from $200.00 to $175.00 in a report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Amedisys has a consensus rating of “Moderate Buy” and a consensus price target of $156.25.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.